Onkologie. 2018:12(2):68-73 | DOI: 10.36290/xon.2018.014

Brest cancer

Milan Brychta
Radioterapeutická a onkologická klinika FNKV a 3. LF UK, Praha

In this article there is a complete look at breast cancer focused on its treatment. It is divided into chapters by the presence of distantmetastasis, the treatment of breast cancer in pregnant women and breast cancer in men. Approach to BRCA positive patients ismentioned too. The effort was to give generalised view on this comprehensive issue.

Keywords: breast cancer, diagnosis, treatment, follow up, BRCA mutation

Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brychta M. Brest cancer. Onkologie. 2018;12(2):68-73. doi: 10.36290/xon.2018.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ústav zdravotnických informací a statistiky ČR, Novotvary 2015. Dostupné z: www.uzis.cz
    2. Onkologická imunologie, Mladá fronta 2015: 199-200, 214.
    3. Léčebný protokol Nádory prsu. Radioterapeutická a onkologická klinika FNKV Praha, 28. 10. 2017
    4. Modrá kniha České onkologické společnosti 2018. dostupneé z: www.linkos.cz
    5. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 20176. Lancet Oncol. 2016; 17(6): 791-800. Go to original source... Go to PubMed...
    6. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Lancet Oncol. 2016; 17(6): 791-800. Go to original source...
    7. Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline - and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study, Annals of Oncology, mdx773, https://doi.org/10.1093/annonc/mdx773
    8. Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017; 377: 122-131. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.